Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Richard Huhn"'
Autor:
Janice Lu, Kevin M Kalinsky, Debu Tripathy, George W Sledge, William Gradishar, Ruth O’Regan, Joyce O’Shaughnessy, Shanu Modi, Joshua Drago, Haeseong Park, Amelia McCartney, Sophia Frentzas, Catherine Shannon, Katharine Cuff, Richard Eek, Miguel Idzwan Martin, Giuseppe Curigliano, Guy Jerusalem, Chiun-Sheng Huang, Michael Press, Matt Li, Dong Xu, Cynthia Song, Richard Huhn, Jinchun Yan, Sara Hurvitz
Publikováno v:
Cancer Research. 82:OT1-02
Background: The HER2 receptor is a cancer driver which is overexpressed on 15-20% of breast cancers. Though historically survival is poor with this disease subtype, HER2+ targeted therapy has improved survival in both early and advanced disease. In s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12f9f807cd7aa4de031734a2f4ea1212
https://doi.org/10.1158/1538-7445.sabcs21-ot1-02-02
https://doi.org/10.1158/1538-7445.sabcs21-ot1-02-02
Autor:
Russell K. Pachynski, Luke Nordquist, Michael T. Schweizer, John Shen, Nabil Adra, Mehmet A. Bilen, Zachery R. Reichert, Rahul Aggarwal, Bilal A. Siddiqui, Matt Li, Dong Xu, Richard Huhn, Darryl Z. L'Heureux, Jinchun Yan, Ying Buechler, Sulan Yao, John Simitzi, Wenge Shi, Shawn Zhang, Scott T. Tagawa
Publikováno v:
Cancer Research. 82:CT211-CT211
Background: Novel anti-PSMA (prostate-specific membrane antigen) targeted therapies have exhibited encouraging antitumor activity in prostate cancer and most non-prostate solid tumors express PSMA in tumor neovasculature. ARX517 is an antibody drug c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9ef54beeace11e69fe9dad9e8a84022
https://doi.org/10.1158/1538-7445.am2022-ct211
https://doi.org/10.1158/1538-7445.am2022-ct211
Autor:
Mary Antonysamy, Nandita Bose, Anissa Chan, Katie Ertelt, Keith Gorden, William Grossman, Richard Huhn, Adria Jonas, Steven Leonardo, Jamie Lowe, Paulette Mattson, Diane McMurray, Mariana Nelson, Nadine Ottoson, Myra Patchen, Xiaohong Qiu, Blaine Rathman, Richard Walsh, Lindsay Wurst, Yumi Yokoyama
Publikováno v:
The Journal of Immunology. 192:73.9-73.9
The innate immune response to Imprime PGG® (Imprime PGG) is being leveraged to develop a novel cancer immunotherapy in conjunction with anti-tumor monoclonal antibodies. Previous research has demonstrated the presence of endogenous anti-β-glucan an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67f7ff51705de0cf23b92f8e0deac4b1
https://doi.org/10.4049/jimmunol.192.supp.73.9
https://doi.org/10.4049/jimmunol.192.supp.73.9
